Background Little work has been done to determine which outcomes should be measured in randomised controlled trials (RCTs) in children with asthma. Drug regulatory authorities require that short term disease activity is measured, but other outcome domains are not mandatory for licensing and marketing purposes. We aimed to identify whether any domains were underrepresented in RCTs of regular therapies for children with asthma over a 20 year period, and to examine what consistency there was between RCTs in the outcomes used to assess the domains. Methodology/Principal Findings By searching the Cochrane Central Register of Controlled Trials in January 2008, we identified all parallel-group RCTs, published between January 1988 and December 2007, which assessed inhaled corticosteroids (ICS) as regular therapy for children with asthma. We evaluated how frequently RCTs measured the following pre-defined domains: disease activity; disease damage; functional status; quality of life; health resource utilisation; and adverse effects of therapy. Our initial search identified 1668 abstracts, of which 412 were retrieved in full. 159 RCTs, of which 115 involved only children and 44 involved children and adults, were included in the review. Disease activity was measured in 157 RCTs, adverse effects of ICS in 135, functional status in 25, quality of life in 21, and health resource utilisation in 17. No RCT measured long term disease damage, although two used FEV1 as a measure of ‘lung growth’. RCTs were inconsistent in the outcomes used to measure the domains. Conclusions Short term disease activity is the most frequently measured outcome domain in RCTs in children with asthma. Effects of regular therapies on functional status, quality of life, and long term consequences of asthma are infrequently assessed. A core set of outcomes, developed using consensus techniques, would standardise the measurement of appropriate outcomes in these RCTs. Involving patients would identify outcomes which are most relevant from their perspective.
References
[1]
Sterk P, Buist S, Woolcock A, Marks G, Platts-Mills T, et al. (1999) The message from the World Asthma Meeting. The Working Groups of the World Asthma Meeting, held in Barcelona, Spain, December 9–13, 1998. Eur Respir J 1999 14(6): 1435–53.
[2]
Masoli M, Fabian D, Holt S, Beasley R (2004) The global burden of asthma: executive summary of the GINA Dissemination Committee Report. Allergy 59(5): 469–78.
[3]
Barnes PJ (2004) The size of the problem of managing asthma. Respiratory Medicine 98: (Supplement 2)S4–S8.
[4]
O'Connell EJ (2004) The burden of atopy and asthma in children. Allergy 59(s78): 7–11.
[5]
Martinez FD (2002) Development of Wheezing Disorders and Asthma in Preschool Children. Pediatrics 109(2): 362–7.
[6]
BTS/SIGN (2008) British Guideline on the Management of Asthma. Thorax 63: (Supplement 4)1–121.
[7]
Altman DG (1991) Practical Statistics for Medical Research. USA: Taylor & Francis Ltd.
Sinha I, Jones L, Smyth RL, Williamson PR (2008) A systematic review of studies that aim to determine which outcomes to measure in clinical trials in children. PLoS Medicine 5(4): e96.
[10]
Smith MA, Leeder SR, Jalaludin B, Smith WT (1996) The asthma health outcome indicators study. Australian & New Zealand Journal of Public Health 20(1): 69–75.
[11]
Tugwell P, Boers M (1993) Developing consensus on preliminary core efficacy endpoints for rheumatoid arthritis clinical trials. Journal of Rheumatology 20(3): 555–6.
[12]
Tugwell P, Boers M, Brooks P, Simon LS, Strand V (2007) An international initiative to improve outcome measurement in rheumatology. Trials 8: 38.
[13]
OMERACT (1993) Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Journal of Rheumatology 20(3): 527–91.
[14]
Miller FW, Rider LG, Chung YL, Cooper R, Danko K, et al. (2001) Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology 40: 1262–73.
[15]
Clarke M (2007) Standardising outcomes for clinical trials and systematic reviews. Trials 8(1): 39.
[16]
Clarke M (2008) Standardising Outcomes in Paediatric Clinical Trials. PLoS Medicine 5(4): e102.
[17]
Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, et al. (1997) Preliminary definition of improvement in juvenile arthritis. Arthritis & Rheumatism 40(7): 1202–9.
[18]
Williamson PR, Gamble C, Altman DG, Hutton JL (2005) Outcome selection bias in meta-analysis. Statistical Methods in Medical Research 14: 515–24.
[19]
Pocock SJ (1983) Clinical Trials: A Practical Approach. Chichester, UK: John Wiley and Sons.
[20]
The Childhood Asthma Management Program Research Group (2000) Long-term effects of budesonide or nedocromil in children with asthma. New England Journal of Medicine 43(15): 1054–63.
[21]
Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen Y-Z, et al. (2003) Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 361(9363): 1071–6.
[22]
U.S. Department of Health and Human Services, FDA (1994) Guidance for industry - clinical development programs for MDI and DPI drug products.
[23]
U.S. Department of Health and Human Services, FDA (2007) Guidance for Industry - Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects of Growth in Children.
[24]
European Medicines Agency (1993) Replacement of Chlorofluorocarbons in Metered Dose Inhalation Products.
[25]
European Medicines Agency (2002) Clinical Investigation of Medicinal Products in the treatment of Asthma.
[26]
European Medicines Agency (2004) Points to Consider on the Requirements for Clinical Documentation for Orally Inhaled Products. Available . Accessed 2009 June 22.
[27]
European Medicines Agency (2007) Requirements for clinical documentation for orally inhaled products including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of asthma and chronic obstructive pulmonary disease. Available . Accessed 2009 June 22.
[28]
Juniper EF, Wisniewski ME, Cox FM, Emmett AH, Nielsen KE, et al. (2004) Relationship between quality of life and clinical status in asthma: a factor analysis. European Respiratory Journal 23(2): 287–91.
[29]
Bacharier LB, Strunk RC, Mauger D, White D, Lemanske RF, et al. (2004) Classifying asthma severity in children: mismatch between symptoms, medication use, and lung function. American Journal of Respiratory & Critical Care Medicine 170(4): 426–32.
[30]
Stahl ECorrelation between objective measures of airway calibre and clinical symptoms in asthma: a systematic review of clinical studies. Respiratory Medicine 94(8): 735–41.
[31]
Turk DC, Dworkin RH, Revicki D, Harding G, Burke LB, et al. Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain 137(2): 276–85.
[32]
Mease PJ, Arnold LM, Crofford LJ, Williams DA, Russell IJ, et al. (2008) Identifying the clinical domains of fibromyalgia: contributions from clinician and patient Delphi exercises. Arthritis & Rheumatism 59(7): 952–60.
[33]
Hewlett S, Carr M, Ryan S, Kirwan J, Richards P, et al. (2005) Outcomes generated by patients with rheumatoid arthritis: how important are they? Musculoskeletal Care 3(3): 131–42.
[34]
Visser MJ, van der Veer E, Postma DS, Arends LR, de Vries TW, et al. (2004) Side-effects of fluticasone in asthmatic children: no effects after dose reduction. Eur Respir Journal 420–5.
[35]
Merkus PJFM, van Pelt W, van Houwelingen JC, van Essen-Zandvliet LEM, Duiverman EJ, et al. (2004) Inhaled corticosteroids and growth of airway function in asthmatic children. Eur Respir Journal 23(6): 861–8.
[36]
James Lind Alliance (2007) Research priorities in Asthma. Description of a workshop to set priorities for treatment uncertainty research in Asthma, March 2007.
[37]
Paton J, Jardine E, McNeill E, Beaton S, Galloway P, et al. (2006) Adrenal responses to low dose synthetic ACTH (Synacthen) in children receiving high dose inhaled fluticasone. Archives of Disease in Childhood 91(10): 808–13.
[38]
Dwan K, Altman DG, Arnaiz JA, Bloom J, Chan A-W, et al. (2008) Systematic Review of the Empirical Evidence of Study Publication Bias and Outcome Reporting Bias. PLoS ONE 3(8): e3081.
[39]
Duncan PW, Jorgensen HS, Wade DT (2000) Outcome measures in acute stroke trials: a systematic review and some recommendations to improve practice. Stroke 31(6): 1429–38.
[40]
Gandhi GY, Murad MH, Fujiyoshi A, Mullan RJ, Flynn DN, et al. (2008) Patient-Important Outcomes in Registered Diabetes Trials. JAMA 299(21): 2543–9.
